Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Xiaoli Wang, Cing Siang Hu, Xiaoping Su, Raajit Rampal, Noushin Farnoud, Erin McGovern, Andrew Davis, Sophia Jiang, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman

Blood (2025) 146 (Supplement 1): 359.

https://doi.org/10.1182/blood-2025-359

Published: 2025

Journal Articles

Long term outcomes of ET and PV patients after clinical trial treatment with interferon alfa

Megan Metzger, Heidi Kosiorek, Ashley Yu, Veer Shah, Nooshin Beygui, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 7345.

https://doi.org/10.1182/blood-2025-7345

Published: 2025

Journal Articles

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Andrew Kuykendall, Rupali Roy, Abdulraheem Yacoub, Marina Kremyanskaya, Aaron Gerds, Ronald Paquette, Jeanne Palmer, Kathryn Johnson, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Ashley Yu, Rami Komrokji, Raajit Rampal, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 483.

https://doi.org/10.1182/blood-2025-483

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Graham Wehmeyer, Ryan Jin, Vesna Najfeld, Megan Metzger, Theodora Anagnostou, Patricia Arboleda Ezcurra, Janice Gabrilove, Marina Kremyanskaya, John Mascarenhas, Christian Salib, Ilan Shapira, Jonah Shulman, Suchitra Sundaram, Douglas Tremblay, Adam Kittai

Blood (2025) 146 (Supplement 1): 5674.

https://doi.org/10.1182/blood-2025-5674

Published: 2025

Journal Articles

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

John Mascarenhas, Justin Johnson, Heidi Kosiorek, Megan Metzger, Tiziano Barbui, Josef Prchal, Alessandro Rambaldi, Abdulraheem Yacoub, Ashley Yu, Ruben Mesa, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, Mohamed Salama

Blood (2025) 146 (Supplement 1): 5590.

https://doi.org/10.1182/blood-2025-5590

Published: 2025

Journal Articles

Low utilization of cancer genetics referrals in newly diagnosed Acute Myeloid Leukemia

Giuseppe Fiorica, Tehilla Brander, Ganesh Sivakumar, Kyle Wiatrowski, Richard Sheppard, Michelle Rudshteyn, Alla Keyzner, Marina Kremyanskaya, Hannah Levavi, Bridget Marcellino, Alan Shih, Lewis R Silverman, John Mascarenhas, Douglas Tremblay, Daniel Nathan, Jonathan Feld

Blood (2025) 146 (Supplement 1): 1085.

https://doi.org/10.1182/blood-2025-1085

Published: 2025

Journal Articles

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Marina Kremyanskaya, Aaron Gerds, Rupali Bhave, Andrew Kuykendall, Eunice Wang, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Kathryn Johnson, Ashley Yu, Anna Rita Migliaccio, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2025-3829

Published: 2025

Journal Articles

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Naveen Pemmaraju, Andrew Kuykendall, Ellen Ritchie, Jason Gotlib, Jeanne Palmer, Aaron Gerds, David Oubre, Prof. Uttam Kumar Nath, Gregory Vosganian, Suneel Gupta, Pedro Oyuela, Sarita Khanna, Arturo Molina, Marina Kremyanskaya

Blood (2025) 146 (Supplement 1): 3810.

https://doi.org/10.1182/blood-2025-3810

Published: 2025

Journal Articles

Modulators of the Hepcidin Pathway in Polycythemia Vera and Myelofibrosis

Marina Kremyanskaya, Yelena Z Ginzburg, Ronald Hoffman

Blood blood.2025028643.

https://doi.org/10.1182/blood.2025028643

Published: 2025

Journal Articles

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Aaron T. Gerds, Andrew T. Kuykendall, Marina Kremyanskaya, Ellen K. Ritchie, Jason Gotlib, Jeanne Palmer, Kristen M. Pettit, Victor Priego, Uttam Kumar Nath, Abdulraheem Yacoub, Arkapal Bandyopadhyay, Suneel Gupta, Sarita Khanna, Arturo Molina, Naveen Pemmaraju

Blood (2024) 144 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2024-197985

Published: 2024

Journal Articles

Acute Promyelocytic Leukemia in the Molecular Age

Navin Bhatt, Michelle Becker, Juana Martinez, Hannah Levavi, Kyle Farina, Marina Kremyanskaya, Bridget Kelly Marcellino, Alan Shih, Lewis R. Silverman, Vesna Najfeld, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld

Blood (2024) 144 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2024-211957

Published: 2024

Journal Articles

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

Marina Kremyanskaya, Ronald Hoffman, Lee Ping Chew, Azizan Sharif, Boyan Semov, Ahlam Naila Kori, Hanlon Sia, Carolyn S. Grove, Ashley P Ng, Akash Kalro, Indu Raman, Ganesh Kasinathan, Olubunmi Oduwole, Monica Gomez-Palou, Henry Fok, Steve Romano, Curtis Rambaran, Alberto Martinez

Blood (2024) 144 (Supplement 1): 656.

https://doi.org/10.1182/blood-2024-205854

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Juana Martinez, Michelle Becker, Megan Metzger, Nagma Shah, Erin Garbes Feliciano, Alberto Busmail Haylock, Navin Bhatt, Nikolaos Spyrou, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld, Marina Kremyanskaya, Michal Bar-Natan, Hannah Levavi

Blood (2024) 144 (Supplement 1): 2798.

https://doi.org/10.1182/blood-2024-212243

Published: 2024

Journal Articles

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

Ariel Siegel, Joseph Tripodi, Brianna Kelly, Sebastian Elghaity-Beckley, Michelle Becker, Douglas Tremblay, Jonathan Feld, Hannah Levavi, Marina Kremyanskaya, Bridget Kelly Marcellino, Christian Salib, Alla Keyzner, Amy Duffield, John O. Mascarenhas, Vesna Najfeld, Alan Shih

Blood (2024) 144 (Supplement 1): 6098.

https://doi.org/10.1182/blood-2024-203588

Published: 2024

Journal Articles

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Ellen K. Ritchie, Kristen Marie Pettit, Andrew T. Kuykendall, Marina Kremyanskaya, Naveen Pemmaraju, Sarita Khanna, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 745.

https://doi.org/10.1182/blood-2023-178253

Published: 2023

Journal Articles

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Blood (2023) 142 (Supplement 1): 321.

https://doi.org/10.1182/blood-2023-181795

Published: 2023

Journal Articles

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Hannah Goulart, Dahniel L Sastow, Nicholas Dreher, Metodi Balev, Grace Van Hyfte, Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Douglas Tremblay

Blood (2023) 142 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2023-182450

Published: 2023

Journal Articles

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Joseph Tripodi, Ronald Hoffman, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Ian Novoselac, Vesna Najfeld

Blood (2023) 142 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2023-181092

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Long term outcomes of ET and PV patients after clinical trial treatment with interferon alfa

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Low utilization of cancer genetics referrals in newly diagnosed Acute Myeloid Leukemia

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Modulators of the Hepcidin Pathway in Polycythemia Vera and Myelofibrosis

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Acute Promyelocytic Leukemia in the Molecular Age

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only